Bristol Myers Squibb Company $BMY Stock Holdings Lowered by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 17.7% in the third quarter, Holdings Channel reports. The firm owned 418,780 shares of the biopharmaceutical company’s stock after selling 89,960 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Bristol Myers Squibb were worth $26,132,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Primecap Management Co. CA bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $1,436,115,000. Legal & General Group Plc acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $980,862,000. BlackRock Inc. raised its position in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares in the last quarter. State Street Corp lifted its holdings in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares during the period. Finally, Caisse de depot et placement du Quebec bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $243,646,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Finally, Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price on the stock in a report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $65.46.

Insider Buying and Selling

In other Bristol Myers Squibb news, Director Julia Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Stock Up 0.2%

Shares of NYSE BMY opened at $62.91 on Thursday. The company has a market cap of $128.59 billion, a price-to-earnings ratio of 13.95, a PEG ratio of 0.32 and a beta of 0.20. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The stock has a 50-day moving average price of $62.09 and a two-hundred day moving average price of $60.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the company posted $1.63 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.45 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.